Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein

被引：0
|
作者：
van Asperen, J
van Tellingen, O
Schinkel, AH
Beijnen, JH
机构：
[1] Netherlands Canc Inst, Dept Clin Chem, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Expt Therapy, NL-1066 CX Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
570
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [21] The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene
    Pippert, TR
    Umbenhauer, DR
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2001, 15 (02) : 83 - 89
  • [22] Effects of P-glycoprotein (P-GP) inhibition on the distribution of domperidone to cardiac tissue: Development of a physiologically based pharmacokinetic model in mdr1a/b(-/-) and wild type mice.
    Fenneteau, F
    Couture, L
    Nash, JA
    Turgeon, J
    Nekka, F
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P49 - P49
  • [23] Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET
    Zoufal, Viktoria
    Wanek, Thomas
    Krohn, Markus
    Mairinger, Severin
    Filip, Thomas
    Sauberer, Michael
    Stanek, Johann
    Pekar, Thomas
    Bauer, Martin
    Pahnke, Jens
    Langer, Oliver
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2020, 40 (01): : 150 - 162
  • [24] Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice
    Kari T. Kivistö
    Jörg Zukunft
    Ute Hofmann
    Mikko Niemi
    Sabine Rekersbrink
    Swetlana Schneider
    Gerd Luippold
    Matthias Schwab
    Michel Eichelbaum
    Martin F. Fromm
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370 : 124 - 130
  • [25] Characterisation of cerivastatin as a P-glycoprotein substrate:: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice
    Kivistö, KT
    Zukunft, J
    Hofmann, U
    Niemi, M
    Rekersbrink, S
    Schneider, S
    Luippold, G
    Schwab, M
    Eichelbaum, M
    Fromm, MF
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 370 (02) : 124 - 130
  • [26] Penetration of the enantiomers of venlafaxine and its metabolites into the brain in mice lacking P-glycoprotein (mdr1ab)
    Carlsson, L.
    Kingback, M.
    Josefsson, M.
    Carlsson, B.
    Ahlner, J.
    Schmitt, U.
    Kugelberg, F. C.
    Hiemke, C.
    Bengtsson, F.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 208 - 208
  • [27] Modulation of the pharmacokinetics of Tc-99m-Q-58 and Tc-99m-sestamibi in MDR1a P-glycoprotein knockout mice.
    Dahlheimer, J
    Crankshaw, CL
    Marmion, M
    PiwnicaWorms, D
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 371 - 371
  • [28] Homozygous disruption of the mdr1a p-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs
    Saito, T
    Zhang, ZJ
    Ohtsubo, T
    Noda, I
    Shibamori, Y
    Yamamoto, T
    Saito, H
    ACTA OTO-LARYNGOLOGICA, 2001, 121 (06) : 735 - 742
  • [29] Distribution of 3H-domperidone, a P-glycoprotein (P-gp) substrate, in heart structures and wholebody tissues of mdr1a (-/-) mice.
    Couture, L
    Nguyen, L
    Tao, L
    Nash, JA
    Turgeon, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P46 - P46
  • [30] Effect of the Mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice
    Desrayaud, S
    De Lange, ECM
    Lemaire, M
    Bruelisauer, A
    De Boer, AG
    Breimer, DD
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 285 (02): : 438 - 443
12345